Erectile Dysfunction Treatment Market to Exhibit a Rise by 6.2% CAGR Between 2019 to 2027 | Mylan Pharmaceuticals Inc, Cipla Ltd, Aurobindo Pharma Ltd, Eli Lily & Co, Novartis International AG, etc
Global Erectile Dysfunction Market – Insights
A recurrent inability of a man to reach and/or to maintain a penile erection sufficient for/during sexual activities is called erectile dysfunction. This medical condition of penis is most likely an age-related factor and a progressive condition that affects some level of disorder (mild, moderate or severe) in about 50% of men aged 40-70 years. Moreover, the severity of the condition increase with growing age with a ratio of about 5% at the age of 50 to 15% at 70 years. Age and secondary medical conditions such as dyslipedemia, diabetes, hypertension, cardiovascular diseases, and depression can be responsible for erectile dysfunction. However, only andrologists, urologists, and sex therapists dealt with the condition in the past. Currently, increasing development in the oral drug therapy for the treatment of erectile dysfunction and growing R&D related to the condition is contributing to growth of the market.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/200
Increasing prevalence of erectile dysfunction is expected to boost growth of the market. For instance, according to a study conducted by Canadian Institute of Health Research, among 4,000 men between the age 40 and 88 years in Canada, 50% suffered from erectile dysfunction. Moreover, the study also revealed that the probability of the condition was two times more in men with cardiovascular diseases and four times more usual in men suffering with any kind of diabetes. Such scenario is expected to increasing demand for Cialis drugs, thereby propelling growth of the erectile dysfunction market.
The global erectile dysfunction market was valued at US$ 4,946.2 million in 2018 and is expected to witness a CAGR of 6.2% during the forecast period (2019 – 2027).
Figure 1. Global Erectile Dysfunction Treatment Market Share (%), By Product Type, 2019 and 2027
Source: Coherent Market Insights Analysis (2019)
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/200
In the recent past, over 31 chemical moiety have advanced into the therapeutic pipeline and 90% of these drugs/molecules are developed by companies and 10% of the molecules/drugs are developed by medical universities and institutes. However, increasing number of molecules and drugs in clinical trials has failed to cater to increasing demand for effective treatment of erectile dysfunction in low income countries. This can be attributed to lack of regional presence of mid-level pharmaceutical companies.
Key players in the market are focused on adopting M&A strategies in order to expand their product portfolio. For instance, in 2014, Endo Pharmaceutical Holdings’ sale of American Medical Systems. In brief, some of the private equity firms are interested to buy American Medical Systems, which is one of the leading manufacturer of products used in the treatment of pelvic disorders of male and female, erectile dysfunction prostheses, and laser technology devices.
According to pharma industry news, in 2012, Viagra drugs dominated the erectile dysfunction market with an approximate market share of about 45% in terms of revenue. The market value for Viagra has declined due to its patent expiry in European countries by 2013. However, some pharmaceutical companies are focused on introducing generic Viagra drug for the treatment of erectile dysfunction. The patent loss has not significantly affected the U.S. market as it has witnessed continuous growth and is expected to maintain its dominant position in the market by 2020.
Cialis accounts for the second largest market share worldwide. However, the segment is expected to witness decline in market share as the patent expiration is due in mid of 2017. Moreover, one of the Bayer’s erectile dysfunction drugs, Levitra/Staxyn is expected to lose its patent by 2018. This in turn is also expected to hinder the market growth over the forecast period. However, presence of around 50 drug molecules under clinical trials and their expected launch in 2018 and 2019 is expected to boost growth of the erectile dysfunction market.
Key Players
Key players operating in the global erectile dysfunction treatment market include Mylan Pharmaceuticals Inc, Cipla Ltd, Aurobindo Pharma Ltd, Eli Lily & Co, Novartis International AG, Torrent Pharmaceuticals Ltd, Pfizer Inc, Bayer Pharma AG, Dr. Reddys Laboratories Ltd, and Dong-A Pharmaceutical Co., Ltd.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/erectile-dysfunction-market-to-surge-past-us-43-billion-by-2024-with-north-america-positioned-as-growth-engine-190
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Supply Side Drivers
- Demand Side Drivers
- Economic Drivers
- Restraints
- Market Opportunities
- Drivers
- PEST Analysis
- Campaigns and Programs
- Pipeline Drugs
- Prevalence and Incidence
- Market Dynamics
- Global Erectile Dysfunction Treatment Market, By Product, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Viagra (Sildenafil Citrate)
- Cialis (Tadalafil)
- Stendra/Sperda
- Levitra/Staxyn
- Zydena (Udenafil)
- Vitaros (Alprostadil Cream)
- Introduction
- Global Erectile Dysfunction Treatment Market, By Distribution Channel, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Introduction
- Global Erectile Dysfunction Treatment Market, By Country, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, By Country, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, For Country, 2017 – 2027
- North America
- Market Size and Forecast, By Product , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Product , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Product , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, By Product , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Product , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- Central Africa
- South Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Mylan Pharmaceuticals Inc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategy
- Cipla Ltd
- Aurobindo Pharma Ltd
- Eli Lily & Co
- Novartis International AG
- Torrent Pharmaceuticals Ltd
- Pfizer Inc
- Bayer Pharma AG
- Dr. Reddys Laboratories Ltd
- Dong-A Pharmaceutical Co., Ltd
- Mylan Pharmaceuticals Inc
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
